Added to YB: 2025-10-24
Pitch date: 2025-10-22
NVO [bullish]
Novo Nordisk A/S
-9.85%
current return
Author Info
Capitalist Letters simplifies investing and makes it understandable for everybody. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 341.00
Price Target
107.00 (-65%)
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
value
5 Quality Stocks You Can Still Buy at Reasonable Prices - Novo Nordisk A/S
NVO: Misunderstood after Cagrisema delivered 22.7% weight loss vs 25% expected, matching Zepbound not beating it. Reality: superior pipeline w/ oral Wegovy (16.6% loss in 64wks vs Lilly's 12.4%), Amycretin (24.3% in 36wks vs Lilly's 24.2% in 48wks). DCF assuming 9% revenue growth shows 2x upside.
Read full article (2 min)